Anika Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anika Therapeutics CEO'su Cheryl Blanchard, Feb2020 tarihinde atandı, in görev süresi 4.75 yıldır. in toplam yıllık tazminatı $ 4.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.3% maaş ve 83.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.2% ine doğrudan sahiptir ve bu hisseler € 2.88M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.2 yıldır.

Anahtar bilgiler

Cheryl Blanchard

İcra Kurulu Başkanı

US$4.5m

Toplam tazminat

CEO maaş yüzdesi	16.3%
CEO görev süresi	4.8yrs
CEO sahipliği	1.2%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	4.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Cheryl Blanchard'un ücretlendirmesi Anika Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$74m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$4m	US$726k	-US$83m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$6m	US$695k	-US$15m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$2m
Dec 31 2021	US$4m	US$668k	US$4m
Sep 30 2021	n/a	n/a	-US$6m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$10m	US$548k	-US$24m
Sep 30 2020	n/a	n/a	-US$4m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$28m
Dec 31 2019	US$187k	n/a	US$27m
Sep 30 2019	n/a	n/a	US$31m
Jun 30 2019	n/a	n/a	US$29m
Mar 31 2019	n/a	n/a	US$30m
Dec 31 2018	US$167k	n/a	US$19m

Tazminat ve Piyasa: Cheryl 'nin toplam tazminatı ($USD 4.46M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 787.21K ).

Tazminat ve Kazançlar: Cheryl 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Cheryl Blanchard (60 yo)

4.8yrs

Görev süresi

US$4,459,800

Tazminat

Dr. Cheryl Renee Blanchard, Ph. D. is Director of Elute, Inc. from May 2013. She serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cheryl Blanchard	President	4.8yrs	US$4.46m	1.2% € 2.9m
Anne Nunes	Senior VP & COO	3.2yrs	US$1.01m	0.092% € 221.3k
David Colleran	Executive VP	4.7yrs	US$1.55m	0.23% € 541.7k
Michael Levitz	Executive Officer	less than a year	US$1.65m	0.32% € 770.9k
Stephen Griffin	Executive VP	less than a year	Veri yok	Veri yok
Ian McLeod	VP & Chief Accounting Officer	no data	Veri yok	Veri yok
Mark Namaroff	Vice President of Investor Relations	no data	Veri yok	Veri yok
James Chase	Senior Vice President of International Sales & Marketing	4.5yrs	Veri yok	Veri yok
Ben Joseph	Vice President of Commercial & Corporate Development	2.8yrs	Veri yok	Veri yok
Lisa Funiciello	Vice President of Human Resources	2.8yrs	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: AKP 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cheryl Blanchard	President	6.3yrs	US$4.46m	1.2% € 2.9m
William Jellison	Independent Director	less than a year	Veri yok	0.018% € 44.3k
John Henneman	Independent Chair of the Board	5.3yrs	US$249.81k	0.20% € 491.5k
Susan L. Vogt	Independent Director	6.1yrs	US$248.98k	0.21% € 497.1k
Sheryl Conley	Independent Director	3.1yrs	US$242.48k	0.14% € 326.8k
Glenn Larsen	Independent Director	9.8yrs	US$237.48k	0.21% € 497.8k
Joseph Capper	Independent Director	less than a year	Veri yok	Veri yok
Gary Fischetti	Independent Director	1.6yrs	US$571.00k	0.089% € 215.2k
Stephen Richard	Independent Director	4.2yrs	US$248.98k	0.19% € 458.6k

4.2yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AKP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

Anika Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. Announces Board Changes

Anika Therapeutics, Inc. Announces CFO Changes

President recently bought €189k worth of stock

Independent Director recently sold €71k worth of stock

Independent Director recently sold €107k worth of stock

Recent updates

Now 41% undervalued after recent price drop

Third quarter 2024 earnings released: US$2.03 loss per share (vs US$0.45 loss in 3Q 2023)

Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: US$0.006 loss per share (vs US$0.19 loss in 2Q 2023)

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.71 loss in 1Q 2023)

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$1.02 loss in FY 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.29 loss in 3Q 2022)

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2022)

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.20 loss in 1Q 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$1.02 loss per share (vs US$0.29 profit in FY 2021)

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.039 profit in 3Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings released: US$0.20 loss per share (vs US$0.45 profit in 2Q 2021)

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 profit in 1Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought €189k worth of stock

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Independent Director recently sold €71k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Revenue misses expectations

New 90-day low: €29.20

Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €34.00

Independent Director recently sold €107k worth of stock

New 90-day low: €27.60

Third quarter 2020 earnings released: US$0.45 loss per share

Revenue beats expectations

Anika Therapeutics, Inc. Suspends Financial Guidance for the Full Year 2020

First half earnings released

Anika Therapeutics, Inc. to Report Q2, 2020 Results on Jul 30, 2020

CEO Tazminat Analizi

CEO